Scandinavian Airlines Brings on Neustar® to Measure Marketing’s Impact on Key Business Drivers
Neustar®, Inc., a trusted, neutral provider of real-time information services, today announced that Scandinavian Airlines, has selected Neustar’s advanced marketing analytics solution to understand the impact of its marketing contributions on sales. Scandinavian Airlines sought a partner like Neustar to drive greater impact of its marketing activities and to pinpoint more efficient marketing investments. As an authoritative, neutral provider connecting analytics to business growth, Neustar MarketShare® will provide Scandinavian Airlines with the data-driven insights to guide day-to-day marketing planning and buying decisions.
Scandinavian Airlines selected Neustar for its industry-leading Marketing Mix Modeling (MMM) approach as it allows the airline to examine key sales channels and essential regions to determine the optimal mix for driving bookings and other business outcomes. In addition, to give Scandinavian Airlines a holistic view across their media activities, Neustar MarketShare models will capture various impact drivers – media, non-media and exogenous (e.g. economy, competition, seasonality, etc.) – to help the airline run scenarios to measure and forecast the impact of changes in any of the drivers. Neustar’s first-class account management team with extensive analytical, strategic and tactical media experience will also assist Scandinavian Airlines with the development of advanced analytics models that value the return on investment (ROI) of marketing channels and tactics.
“Understanding the key drivers on our business and ensuring we allocate marketing spend where we see the highest returns, whilst mitigating any revenue risks, are essential to SAS,” said Didrik Fjeldstad, Vice President, Brand and Marketing, SAS. “Building a robust analytics and ROMI measurement practice is of utmost importance to us as it ensures we optimize our media spend whilst mitigating any risk to the business. Working with a partner like Neustar will allow us to make much faster and smarter decisions about our marketing investments and increase profitability.”
Scandinavian Airlines is taking a laser-focused approach to building a standard framework for measuring the return on marketing investment (ROMI) across its three major markets – Denmark, Norway and Sweden. By building a robust ROMI culture across its organization and geographic footprint, Scandinavian Airlines will be able to allocate marketing expenditures more efficiently and shift spend to high performing channels, markets and activities. In doing so, it is bringing the marketing intelligence decisions in-house and with its appointed media agencies and platforms, creating a more transparent media measurement and attribution process. For example, Scandinavian Airlines can now access the Neustar MarketShare always-on measurement and optimization platform to be predictive in how they most effectively and efficiently plan and deploy media.
“Now more than ever marketers want to distinguish between marketing activities that are driving business value and those that don’t,” said Luis Chaves, Managing Director, Marketing Solutions EMEA, Neustar. “Marketers who take a holistic and unified approach to marketing analytics and measurement will undoubtedly outsmart the competition. We are thrilled to be working with such a highly regarded and forward-thinking European airline to help them make better and faster decisions.”
The Neustar MarketShare Marketing Planning and Allocation solution offers advertisers a guide to budgeting and planning decisions, as well as trade-off scenarios for allocations – predictively – across products, markets, segments and channels. It takes into consideration both the offline marketing tactics and the non-media drivers (e.g. weather, economic indicators, competitor actions, etc.) in order to help clients examine the true value of their marketing performance. Marketers can build an optimal marketing plan to boost their revenue and more accurately allocate their marketing resources, course correcting to improve ROMI. The Neustar MarketShare next-generation tool for unified marketing impact analytics keeps pace with the rapidly changing marketing landscape to assure that marketers are maximizing their business results and proving marketing’s contribution to revenue at every opportunity.
Neustar, Inc. is a leading global information services provider driving the connected world forward with trusted, holistic identity resolution. As the only company capable of understanding who is on the other end of every interaction, Neustar is trusted by the world’s great brands to grow and guard their businesses with the most complete knowledge of how to connect people, places and things. The combination of Neustar’s unique, accurate, and real-time identity system and our cloud-based workflow solutions empower our clients to make actionable, precise and valuable decisions across marketing, risk, IT/security, network and operations departments. More information is available at https://www.home.neustar.
About Scandinavian Airlines (SAS)
SAS carries more than 30 million passengers annually and is Scandinavia's leading airline with close to 800 daily flights on 272 routes to 123 destinations in Scandinavia, Europe, USA and Asia. SAS is a member of Star Alliance™ and can together with our partner airlines offer more than 18,400 daily flights to 1,300 destinations around the world in over 191 countries. For more information, visit www.flysas.com.
Neustar Media Contact
Hotwire Global (on behalf of Neustar)
+44 07393 465 537
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
BioNTech Signs Collaboration Agreement with Pfizer to Develop mRNA-based Vaccines for Prevention of Influenza16.8.2018 08:00 | Tiedote
BioNTech AG, a rapidly growing biotechnology company focused on precise immunotherapies for the treatment of cancer and infectious disease, today announced that it has entered into a multi-year research and development (R&D) collaboration with Pfizer Inc. (NYSE: PFE) to develop mRNA-based vaccines for prevention of influenza (flu). Under the terms of the agreement, BioNTech and Pfizer will jointly conduct research and development activities to help advance mRNA-based flu vaccines. Pfizer will assume sole responsibility for further clinical development and commercialization of mRNA-based flu vaccines, following BioNTech’s completion of a first in human clinical study. BioNTech will receive $120 million in upfront, equity and near-term research payments and up to an additional $305 million in potential development, regulatory and commercial milestone payments. In addition, BioNTech will receive up to double-digit tiered royalty payments associated with worldwide sales if the program reac
Maxion Wheels to Showcase Market-Leading Light Weight Commercial Vehicle Wheels at REIFEN 201816.8.2018 07:05 | Tiedote
Maxion Wheels, the world’s largest producer of wheels, announced today its participation in REIFEN, the leading tire and wheel industry event in Europe, from Sept. 11 – 15, 2018 in Hall 12.1 / Stand D24. For the first time, REIFEN will be co-located with Automechanika Frankfurt at the Messe Frankfurt. “REIFEN is the premier event for European tire and wheel manufacturers and resellers, bringing us together to meet and collaborate on the important aftermarket themes of innovation, service and delivery,” stated Mark Gerardts, Vice President of Global Sales and Marketing, Maxion Wheels. “After a highly popular launch to truck and trailer OEMs in 2017, we’re excited to have the industry’s lightest mass production steel wheel now available to our aftermarket distributors. This wheel, along with several others, including our new 10.00W-20 wide base tubetype and tubeless heavy duty armored vehicles wheel are great examples of our continued efforts to bring our OE multi-application innovations
Lenovo Accelerates Turnaround with Back-to-Back, Double-Digit Quarterly Revenue Growth16.8.2018 02:40 | Tiedote
Lenovo Group (HKSE: 0992) (PINK SHEETS: LNVGY) today announced results for its first fiscal quarter ended June 30, 2018. For the second straight quarter, Lenovo achieved strong double-digit growth in revenue year-on-year. Group revenue reached US$11.91 billion, up 19% year-on-year. The company also reported strong pre-tax income during the quarter of US$113 million, an improvement of US$182 million year-on-year, as profitability improved across all businesses. In the first fiscal quarter, Lenovo’s profit attributable to equity holders grew to US$77 million, up US$149 million year-over-year. Basic earnings per share in the first fiscal quarter was 0.65 US cents or 5.10 HK cents. “As we persistently execute our 3-wave strategy, all our businesses made solid improvements in both revenue and profitability. Lenovo has passed the turning point and entered a phase of ‘acceleration’ - accelerating the execution of our transformation strategy and accelerating the rising momentum in business per
CORRECTING and REPLACING Ebola Successfully Neutralized by Latest Generation Polyclonal Immunotherapy16.8.2018 01:37 | Tiedote
Please replace the release with the following corrected version due to multiple revisions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180815005602/en/ New Ebola immunotherapy developed by SAB Biotherapeutics uses natural human polyclonal antibodies to combat disease. (Photo: SAB Biotherapeutics) The corrected release reads: EBOLA SUCCESSFULLY NEUTRALIZED BY LATEST GENERATION POLYCLONAL IMMUNOTHERAPY Promising new platform can rapidly respond to emerging infectious diseases Sioux Falls, SD, August 15, 2018 – SAB Biotherapeutics, Inc. (SAB), a clinical-stage biopharmaceutical company, today announced that its anti-Ebola immunotherapy (SAB-139) provided “100% protection against a lethal dose of the Ebola virus” in a recent animal study published in The Journal of Infectious Diseases . The study was conducted at the Integrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of He
QConnect – Markkinoiden älykkäin, erittäin kompakti ja lujatekoinen viestintälaite15.8.2018 23:23 | Tiedote
Quake Global, Inc. (QUAKE), yksi maailman johtavista IoT-markkinoiden toimittajista, julkaisi QConnect™, uuden sukupolven kehittyneen telematiikkalaitteen. Äärimmäisen kompakti QConnect integroituu kiinteisiin ja liikkuviin omaisuuksiin niiden seuraamiseksi, valvomiseksi ja hallitsemiseksi reaaliajassa mistä ja milloin tahansa. Laite tarjoaa useita pitkälle kehitettyjä langattomia kommunikaatiovaihtoehtoja, mukaan lukien LTE/2G/3G, kaksitaajuus-Wi-Fi, Bluetooth/BLE, V2X ja satelliitti. Laite on suunniteltu vastaamaan moniin eri vaatimuksiin yksinkertaisista ja edullisista seurantasovelluksista aina korkean suorituskyvyn monikanavaisiin videon suoratoistosovelluksiin. Tämä lehdistötiedote sisältää multimediaa. Katso koko julkaisu täällä: https://www.businesswire.com/news/home/20180815005706/fi/ Quake Global’s new QConnect, the most intelligent, global, ultra-compact and rugged communication device available (Photo: Business Wire) QConnect tarjoaa joustavuutta sen ainutlaatuisilla sovell
Ebola Successfully Neutralized by Latest Generation Polyclonal Immunotherapy15.8.2018 20:43 | Tiedote
SAB Biotherapeutics, Inc. (SAB), a clinical-stage biopharmaceutical company, today announced that its anti-Ebola immunotherapy (SAB-139) provided “100% protection against a lethal dose of the Ebola virus” in a recent animal study published in The Journal of Infectious Diseases . The study was conducted by the National Interagency Confederation for Biological Research and other collaborators including United States Army Medical Research Institute of Infectious Diseases (USAMRIID) and the Naval Medical Research Center (NMRC). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180815005602/en/ New Ebola immunotherapy developed by SAB Biotherapeutics uses natural human polyclonal antibodies to combat disease. (Photo: SAB Biotherapeutics) According to the World Health Organization, Ebola virus disease (EVD), formerly known as Ebola hemorrhagic fever, is a severe, often fatal illness in humans with an average fatality rate around 50%.
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme